Market closed · After hours · 6:09 PM ET
Last update: Jul 20, 2026, 5:23 PM ET
Eli Lilly and Company
$1,146.85 2.74% today
After Hours

Why Eli Lilly and Company (LLY) stock moved

Updated Jul 20, 2026

Eli Lilly and Company (LLY) shares fell 2.7% to $1,146.85 as of July 20, 2026, a moderate decline from the prior close of $1,179.11. BestStocks flagged the session as a major change for LLY. Below, we break down what changed for LLY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

LLY fell 2.7% to $1146.85

LLY fell 2.7% in its latest session, moving from $1,179.11 to $1,146.85.

ActivityCompany-Specific MoveWeak confidence
Rel. volume
0.6×
Below Avg
Vs peers
Top 7 of 7 peers
Underperforming
Market cap
$1.1T
New York Stock Exchange
Analyst target
$1315
+14.7% vs price
Price chart
Jul 20
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Eli Lilly and Company investors

For Eli Lilly and Company investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Negative session, down 2.7%; LLY declined 3.13% to $1191.42 intraday, despite a Yahoo Finance headline reporting Lilly hitting new highs alongside J&J and AbbVie. Because the move outpaced peers, it looks driven by LLY-specific developments rather than a broad sector rotation. Wall Street's consensus price target sits at $1,315.42, implying +14.7% upside from $1,146.85. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 16 days out, the next report is the most likely near-term test of the move.

LLY price reaction

LLY last traded at $1,146.85, down $32.26 (-2.74%) from the previous close of $1,179.11. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -1.2% over the same stretch, leaving LLY behind the group by 1.5 points.

Bullish and bearish analyst opinions on Eli Lilly and Company (LLY)

The consensus analyst price target on Eli Lilly and Company (LLY) is $1,315.42, 14.7% above the recent $1,146.85. Over the past 90 days analysts logged 0 upgrades, 18 maintains, and 0 downgrades. Here is how the bullish and bearish cases on LLY line up.

The bullish case

  • Wall Street's consensus price target of $1,315.42 implies +14.7% upside from $1,146.85.
  • The Street's most bullish target is $1,500.00 (+30.8%).
  • Positive price momentum.
  • LLY surged 7.13% to $1,208.12, hitting an all-time high.

The bearish case

  • The most bearish analyst target is $1,135.00 (-1.0%).
  • Negative session, down 2.7%.
  • LLY declined 3.13% to $1191.42 intraday, despite a Yahoo Finance headline reporting Lilly hitting new highs alongside J&J and AbbVie.
  • LLY fell 3.20% to $1190.63 intraday despite a Yahoo Finance headline reporting "Lilly, J&J and AbbVie Hit New Highs." Volume is running at 1.08x expected levels for this point in the session.
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Jul 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $1315+14.7%
= 18 maintains
Citigroup maintained Buy · 2026-07-15
SEC filings watch
8-K2026-05-20
Material event — review for impact
high
8-K2026-05-07
Material event — review for impact
high
10-Q2026-04-30
Quarterly financial results
medium
8-K2026-04-30
Material event — review for impact
high
Peer context
LLY-2.7%
UNH-1.1%
JNJ-1.7%
PFE-1.2%
ABBV-0.4%
MRK-2.4%

Previous notable changes for LLY

Risk2026-07-20
Eli Lilly and Company (LLY) moved -2.74% from $1179.11 to $1146.85 on 2026-07-20. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the move lacked unusual market participation.
Valuation2026-07-02via 247wallst.com
Eli Lilly announced a distribution and promotion agreement with Innovent Biologics to commercialize breast cancer therapy Verzenios (abemaciclib) in mainland China on July 1, 2026. The stock is up 3.34% intraday to $1,215.95.
News
Medicare begins covering GLP-1 obesity drugs for seniors at $50/month copay, expanding eligible patient population.
News
FDA selected LLY for PreCheck pilot program enabling expedited review of new manufacturing facilities.
Upcoming catalysts & outlook
Next earnings
2026-08-05 (est.)
in 16 days
Earnings Release
2026-08-05
High impact
Thesis shift
Bearish Shift
bearish signal
Risk level
High
from change events

Frequently asked questions about LLY

Why did Eli Lilly and Company (LLY) stock move?

LLY fell 2.7% to $1,146.85. No single company-specific catalyst was confirmed during the move window, and it looks like a company-specific move.

How much did LLY stock fall?

LLY lost 2.74% ($32.26) versus the prior close of $1,179.11, last trading at $1,146.85 on 0.6× average volume.

When is Eli Lilly and Company's next earnings date?

LLY's next earnings report is estimated for 2026-08-05 — about 16 days away.

What is the analyst price target for LLY?

The consensus analyst price target for LLY is $1,315.42, about 14.7% above the current $1,146.85. Over the past 90 days, analysts recorded 0 upgrades, 18 maintains, and 0 downgrades.

Is the LLY move company-specific or sector-wide?

BestStocks classifies it as a company-specific move: the peer group moved a median -1.2% against LLY's -2.7%. LLY ranks top 7 of 7 peers.

How BestStocks tracks LLY

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared LLY-specific materiality thresholds, triggering an evidence check. It draws on 13 tracked change events for LLY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.